The PurpleLab^® Resource Center

This research, led by Grace K. Kane, Douglas Londono, and Nathan J. Markward, explores how the timing of biomarker testing affects survival outcomes in patients with non-small cell lung cancer (NSCLC). Using real-world claims data, it identifies disparities in testing and treatment patterns and their impact on mortality rates. Biomarker testing is essential to advancing…

Headache disorders including migraine are highly prevalent globally, estimated to affect more than 50% of the population at any point and time. In the U.S., migraine patients spend an average of $9,000 more than those without the diagnosis.

Price transparency mandates have introduced an unprecedented volume of data — but turning that data into actionable strategy remains a challenge. Health systems and payers alike are still navigating how to translate pricing insights into stronger contract terms, smarter network expansion and more aligned pricing strategies.